Ann Lab Med.  2020 Jan;40(1):1-6. 10.3343/alm.2020.40.1.1.

JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma

• Kim MS
• Park CJ
• Cho YU
• Jang S
• Seo EJ
• Park CS
• Huh J
• Im HJ
• Seo JJ
• Yoon DH
• Suh C

• KMID: 2457486
• DOI: http://doi.org/10.3343/alm.2020.40.1.1

Abstract

BACKGROUND
JL1, a CD43 epitope and mucin family cell surface glycoprotein, is expressed on leukemic cells. An anti-JL1 antibody combined with a toxic substance can have targeted therapeutic effects against JL1-positive leukemia; however, JL1 expression on bone marrow (BM) lymphoma cells has not been assessed using flow cytometry. We investigated JL1 expression on BM lymphoma cells from patients with non-Hodgkin lymphoma (NHL) to assess the potential of JL1 as a therapeutic target.
METHODS
Patients with BM involvement of mature B-cell (N=44) or T- and natural killer (NK)-cell (N=4) lymphomas were enrolled from May 2015 to September 2016. JL1 expression on BM lymphoma cells was investigated using flow cytometry. Clinical, pathological, and cytogenetic characteristics, and treatment responses were compared according to JL1 expression status.
RESULTS
Of the patients with NHL and BM involvement, 37.5% (18/48) were JL1-positive. Among mature B-cell lymphomas, 100%, 38.9%, 33.3%, 100%, and 25.0% of Burkitt lymphomas, diffuse large B-cell leukemias, mantle cell leukemias, Waldenstrom macroglobulinemia, and other B-cell lymphomas, respectively, were JL1-positive. Three mature T- and NK-cell NHLs were JL1-positive. JL1 expression was associated with age (P=0.045), complete response (P=0.004), and BM involvement at follow-up (P=0.017), but not with sex, performance status, the B symptoms, packed marrow pattern, cytogenetic abnormalities, or survival.
CONCLUSIONS
JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy.

Keyword

JL1 expression; Flow cytometry; Mature B-cell lymphoma; T- and natural killer-cell lymphoma

MeSH Terms

B-Lymphocytes
Bone Marrow*
Burkitt Lymphoma
Chromosome Aberrations
Cytogenetics
Drug Therapy
Flow Cytometry
Follow-Up Studies
Humans
Leukemia
Leukemia, B-Cell
Lymphoma*
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin*
Membrane Glycoproteins
Mucins
Therapeutic Uses
Waldenstrom Macroglobulinemia
Membrane Glycoproteins
Mucins
Therapeutic Uses

Figure

• 

  Fig. 1 Measurement of JL1 expression on lymphoma cells by flow cytometry in a patient with follicular lymphoma and bone marrow involvement. Mononuclear lymphoma cells were isolated by gating intermediate to bright CD45-APC expression and low SSC (A), CD19+ B-lymphoma cells were isolated by gating intermediate to bright CD45-APC and positive CD19-FITC stained cells (B), and the proportion of JL1-expressing lymphoma cells among B-lymphoma cells was calculated using a CD19-FITC vs JL1-PE dot plot (C). The results of JL1 expression analysis are presented as the proportion of JL1-positive cells among gated lymphoma cells (24.3% in this case).Abbreviations: CD, cluster of differentiation; SSC, side scatter; FSC, forward scatter; PE, phycoerythrin; APC, allophycocyanin.

Reference

1. Park CS, Park SH. Diagnostic usefulness of monoclonal antibody for T lymphoblastic lymphoma/acute lymphoblastic leukemia-specific JL1 antigen in paraffin embedded tissue. Korean J Pathol Trans Med. 1999; 33:1033–1038.

2. Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, et al. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol. 2001; 158:1473–1480. PMID: 11290565.

3. Park SH, Bae YM, Kwon HJ, Kim TJ, Kim J, Lee SJ, et al. JL1, a novel differentiation antigen of human cortical thymocyte. J Exp Med. 1993; 178:1447–1451. PMID: 8376947.

4. Chung JK, So Y, Hong MK, Choi SR, Jeong JM, Lee DS, et al. In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1. Nucl Med Biol. 1997; 24:433–437. PMID: 9290079.

5. Park WS, Bae YM, Chung DH, Kim TJ, Choi EY, Chung JK, et al. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias. Leukemia. 1998; 12:1583–1590. PMID: 9766503.

6. Kim S, Hong JW, Cho WD, Moon YR, Yoon SS, Kim MY, et al. Characterization of two novel mAbs recognizing different epitopes on CD43. Immune Netw. 2014; 14:164–170. PMID: 24999313.

7. Kim TJ, Park SH. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. J Korean Med Sci. 1998; 13:455–458. PMID: 9811172.

8. Chung J, Park S, Kim D, Rhim J, Kim I, Choi I, et al. Identification of antigenic peptide recognized by the anti-JL1 leukemia-specific monoclonal antibody from combinatorial peptide phage display libraries. J Cancer Res Clin Oncol. 2002; 128:641–649. PMID: 12474050.

9. Park YS, Park SH, Park SJ, Kim Y, Jang KT, Ko YH, et al. Expression of JL1 is an effective adjunctive marker of leukemia cutis. Arch Pathol Lab Med. 2010; 134:95–102. PMID: 20073611.

10. Shin YK, Choi YL, Choi EY, Kim MK, Kook MC, Chung J, et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol Immunother. 2003; 52:506–512. PMID: 12768327.

11. Hwang I, Go H, Jeon YK, Ko YH, Yoon DH, Suh C, et al. Expression of JL1 in Burkitt lymphoma is associated with improved overall survival. Virchows Arch. 2011; 459:353–359. PMID: 21814778.

12. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127:2375–2390. PMID: 26980727.

13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649–655. PMID: 7165009.

14. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368:1408–1416. PMID: 23574119.

15. Freedman AS, Jacobson CA, Mauch P, Aster JC. Non-Hodgkin's lymphoma. In : DeVita VT, Lawrence TSR, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins;2015. p. 1552–1587.

16. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014; 12:1282–1303. PMID: 25190696.

17. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016; 14:1067–1079. PMID: 27587620.

18. El-Sayed AM, El-Borai MH, Bahnassy AA, El-Gerzawi SM. Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry. Diagn Pathol. 2008; 3:43. PMID: 18986555.

19. Gruss HJ, Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma. 1996; 20:397–409. PMID: 8833395.

20. You E, Kim S, Park CJ, Jang S, Cho YU, Yoon CH, et al. JL1 antigen expression of leukemic cells in childhood acute leukemia. Haematologica. 2017; 102:353.

21. Park HS, Lee JH, Lee JH, Kim DY, Choi EJ, Hur EH, et al. Expression of JL1 antigen in acute leukemia and myelodysplastic syndrome. Blood. 2015; 126:3826.

22. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97:3370–3379. PMID: 11369626.

23. Zhao X, Pogue S, Lin J, Bi M, Wilson Dand Hsi ED. JL1 is a cell surface molecule of acute leukemia blasts: potential for targeted immunotherapy. Cancer Res. 2012; 72:2525.

24. Lee GK, Jung KC, Park WS, Kook MC, Park CS, Sohn HW, et al. LFA-1- and ICAM-1-dependent homotypic aggregation of human thymocytes induced by JL1 engagement. Mol Cells. 1999; 9:662–667. PMID: 10672935.